A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned (relapsed) or not responded to treatment (refractory) or have higher risk Myelofibrosis (MF). Participants will receive a study drug infusion on Day 1, Day 4, Day 8 and Day 11 of each 28-day cycle for a total of 6 cycles.

Trial Details

NCT ID

NCT07250646

Phase

PHASE1

Sponsor

Aspera Biomedicines, Inc.

Status

RECRUITING

Cancer Type

Leukemia

Interventions

rebecsinib

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
Sacramento, California, United States|38.58157,-121.4944
San Diego, California, United States|32.71571,-117.16472

Key Eligibility Criteria

Ability to understand and the willingness to sign a written informed consent.
Must have a refractory myeloid neoplasm (5th Edition WHO Classification of Tumors) consisting of secondary AML (sAML), which has evolved from antec…
Calculated Creatinine clearance (CrCl) \> 60 mL/min (based upon the Cockcroft- Gault Equation \[CrCl = (140-age) \* ideal body wt (in kg) \* (0.85 …
Has recovered from the toxic effects of prior therapy to their clinical baseline.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →